American Society of Hirudotherapy

Hirudin reduces tissue factor expression and attenuates graft arteriosclerosis in rat cardiac allografts

Research article published in Circulation (2000)

Last Updated: November 1, 2026ASH Editorial · based on the books
Research article — evidence review: Off-label use means application outside the FDA-cleared indication. Clinical evidence (RCTs or systematic reviews) supports this use, but the FDA has not cleared it.Article reference: Content describes science, methodology, or organizational reference material — not a clinical efficacy claim.
Evidence: Preclinical (animal)Drug DevelopmentHölschermann H et al. · Circulation, 2000

Abstract

BACKGROUND-Intravascular clotting has been implicated in the pathogenesis of cardiac allograft vasculopathy (CAV). We previously identified the expression of tissue factor (TF), the primary cellular initiator of blood coagulation, within the coronary intima, which was associated with neointimal thickening. In the present study, the effect of recombinant hirudin on CAV was assessed in Lewis to Fisher rat heterotopic cardiac allografts. METHODS AND RESULTS-Transplant recipients were randomized to a control group (n=10) and a hirudin-treated group (n=12; 2 mg. kg(-1). d(-1) SC). Histological evaluations of rejection, CAV, and TF staining were performed 120 days after transplantation. No significant differences were observed between the 2 groups with respect to the degree of rejection. Hirudin significantly (P<0.05) suppressed the development of CAV in the graft microvessels, but it was less effective in large coronary arteries. Graft intimal cells, isolated by laser-assisted cell picking, showed a marked upregulation of TF gene transcription, which was prevented by hirudin (P<0.01). As demonstrated by immunohistochemistry and quantitative analyses of TF mRNA levels by real-time polymerase chain reaction, hirudin treatment resulted in a significant reduction of TF protein and mRNA expression (P<0.001). CONCLUSIONS-Treatment with hirudin in this rat cardiac transplant model inhibited TF expression and decreased neointimal hyperplasia. These results suggest that TF inhibition by hirudin, in addition to its direct effect on thrombin, may attenuate the hypercoagulable state and prevent the development of CAV at least in restricted sites of the graft coronary vasculature.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsAnimalsCoronary Artery DiseaseCoronary VesselsHeart TransplantationHirudinsMalePostoperative PeriodRatsRats, Inbred F344Rats, Inbred LewThromboplastinTransplantation, Homologous

Summary

In Lewis-to-Fisher rat cardiac allografts, recombinant hirudin (2 mg/kg/day subcutaneously) suppressed graft microvessel arteriosclerosis and markedly reduced intimal tissue factor mRNA and protein expression, suggesting tissue factor inhibition beyond direct thrombin blockade.

Why This Matters for Hirudotherapy

This study investigated the effect of recombinant hirudin on cardiac allograft vasculopathy (CAV) in a rat heterotopic cardiac transplant model, with recipients randomized to control (n=10) or hirudin treatment (n=12) groups evaluated at 120 days post-transplantation. Hirudin significantly suppressed CAV development in graft microvessels and reduced both tissue factor gene transcription and protein expression, though it was less effective in large coronary arteries and did not significantly alter the degree of rejection. The abstract frames the mechanism in terms of tissue factor inhibition and attenuation of a hypercoagulable state. However, these results are limited to a rat model using a purified recombinant formulation, and the abstract does not discuss leeches, whole-organism hirudotherapy, or human clinical application.

Citation

Reference (Vancouver style)

Hölschermann H, Bohle RM, Schmidt H, Zeller H, Fink L, Stahl U, et al. Hirudin reduces tissue factor expression and attenuates graft arteriosclerosis in rat cardiac allografts. Circulation. 2000;102(3):357-363. doi:10.1161/01.cir.102.3.357. PMID: 10899102

Bibliographic details (authors, volume, pages, DOI) are taken from the PubMed record.

Added to ASH library: May 27, 2026 · Site last updated: November 1, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.